Close Menu

More articles about Business, Policy & Funding

The clearance covers tests made by the firm's joint venture for manufacturing, CoSara Diagnostics, in its facility in Ranoli, India.

Working with MPEG-G booster GenomSys, SysMeta IT will integrate the new data compression specification into its Tangerine Medical platform to support clinicians.

ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.

The platform matches a patient's medical history and other data with national guidelines to recommended medically actionable genetic tests.

The GenomeWeb Index outperformed the Dow Jones and the Nasdaq, but underperformed the Nasdaq Biotechnology Index this month.

BTIG gave Centogene a Buy rating, while SVB Leerink and Evercore ISI each gave the company an Outperform rating. 

The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.

The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.

In a notice posted on its website, the Competition and Markets Authority said it is extending its inquiry, with a new deadline of Feb. 5, 2020.

The financing will go toward building out its sales teams in the US and Europe in order to market its multiplexed MDx tests for infectious diseases.

Geisinger researchers will work with collaborators at the nonprofit FH Foundation to develop new methods for the identification and cascade testing of FH.

The test, which will be developed using the companies' respective technologies, will be marketed by Biolidics following clinical validation.

The firm's diagnostics and genomics group saw a 5 percent year-over-year revenue increase in the fourth quarter.

A regional court said certain 10x Genomics' products, including older GEM chips and some Chromium instruments, infringed a "utility model," similar to a patent.

PWNHealth will enable Stratify to offer its Prompt Personal Genetic Score prostate cancer genetic risk test directly to consumers with medical oversight.

ONT called Illumina's revised remedies proposal an "illusory offer" that doesn't offset the anticompetitive effects of an Illumina-PacBio merger.

Athena and its supporters have asked the Supreme Court to clarify patent eligibility, but Mayo recently countered that this is a job for legislators.

Asuragen will use its Amplidex PCR tech to develop companion diagnostics for Wave's investigational allele-selective therapeutic programs for Huntington's.

The company also said that it expects a clearance decision from US regulators in the near term on a lower respiratory tract infection test that runs on its Unyvero system.

Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease and breast cancer.

Pages

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.